{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:08:28Z","timestamp":1789124908628,"version":"build-2803163510"},"reference-count":363,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 2025, the 50th anniversary of the invention of hybridoma technology, the United States Food and Drug Administration (US FDA) approved a total of 44 new molecular entities (NMEs), of which 10 were therapeutic antibody-based molecules. Additionally, the US FDA approved 31 small molecules (of which one was a peptide), and 3 new nonantibody therapeutic proteins, but no new chimeric antigen receptor (CAR)-T-cell therapeutics. Of the new antibody-based biologics, two were antibody\u2013drug conjugates, one was a T-cell engager\u2013bispecific antibody, two were Fc-modified, half-life extended antibodies, and two targeted the complex coagulation pathway. The eighth novel anti-PD-1 antibody was also approved, along with the newest entry of biologics targeting the neonatal Fc receptor (FcRn). Additionally, two new entries in which hyaluronidase was coformulated with an antibody to provide rapid subcutaneous dosing were FDA-approved. Finally, the first antibody-like scaffold-fusion protein was approved that will compete in an antibody-rich environment.<\/jats:p>","DOI":"10.1093\/abt\/tbag027","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T11:41:13Z","timestamp":1779968473000},"page":"332-366","source":"Crossref","is-referenced-by-count":0,"title":["Structure and function of therapeutic antibodies approved by the US FDA in 2025"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6875","authenticated-orcid":false,"given":"William R","family":"Strohl","sequence":"first","affiliation":[{"name":"Scientific Advisor Department, BiStro Biotechnology Consulting , 1086 Tullo Farm Rd., 08807 Bridgewater, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"2026091106322338900_ref1","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"2026091106322338900_ref2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1126\/science.6387914","article-title":"The 1984 Nobel Prize in medicine","volume":"226","author":"Uhr","year":"1984","journal-title":"Science"},{"key":"2026091106322338900_ref3","volume-title":"Bistro Biotech Consulting LLC Antibody Database","author":"Strohl"},{"key":"2026091106322338900_ref4","first-page":"92. 17 March 2026,","volume-title":"2025 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref5","volume-title":"U.S. Food and Drug Administration"},{"key":"2026091106322338900_ref6","volume-title":"2025 Biological License Application Approvals"},{"key":"2026091106322338900_ref7","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"2026091106322338900_ref8","doi-asserted-by":"publisher","first-page":"2614669","DOI":"10.1080\/19420862.2026.2614669","article-title":"Antibodies to watch in 2026","volume":"18","author":"Crescioli","year":"2026","journal-title":"MAbs"},{"key":"2026091106322338900_ref9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/abt\/tbaf014","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2024","volume":"8","author":"Strohl","year":"2025","journal-title":"Antib Ther"},{"key":"2026091106322338900_ref10","author":"Ingram I","journal-title":"MedPageToday"},{"key":"2026091106322338900_ref11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/abt\/tbae007","article-title":"Structure and function of therapeutic antibodies approved by the US FDA in 2023","volume":"7","author":"Strohl","year":"2024","journal-title":"Antib Ther"},{"key":"2026091106322338900_ref12","first-page":"39,","volume-title":"2014 Sales of Recombinant Therapeutic Antibodies & Proteins","year":"2026"},{"key":"2026091106322338900_ref13","first-page":"39,","volume-title":"2015 Sales of Recombinant Therapeutic Antibodies & Proteins","year":"2026"},{"key":"2026091106322338900_ref14","first-page":"39,","volume-title":"2016 Sales of Recombinant Therapeutic Antibodies & Proteins","year":"2026"},{"key":"2026091106322338900_ref15","first-page":"53,","volume-title":"2017 Sales of Recombinant Therapeutic Antibodies & Proteins","year":"2026"},{"key":"2026091106322338900_ref16","first-page":"55,","volume-title":"2018 Sales of Recombinant Therapeutic Antibodies & Proteins","year":"2026"},{"key":"2026091106322338900_ref17","first-page":"65,"},{"key":"2026091106322338900_ref18","first-page":"88,","volume-title":"2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref19","first-page":"66,","volume-title":"2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref20","first-page":"71,","volume-title":"2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref21","first-page":"77,","volume-title":"2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref22","first-page":"84,","volume-title":"2024 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics","year":"2026"},{"key":"2026091106322338900_ref23","volume-title":"Fortune Business Insights, Report ID: FBI102734"},{"key":"2026091106322338900_ref24","volume-title":"Drug Approvals: Despite FDA Tumult and Macro Uncertainty, Biopharma Scored with 55 New","author":"Dunleavy","year":"2025"},{"key":"2026091106322338900_ref25","first-page":"708","volume-title":"WHO Drug Info","author":"Datopotamabum deruxtecanum","year":"2020"},{"key":"2026091106322338900_ref26","volume-title":"US License No. 2128","author":"Datroway\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref27","doi-asserted-by":"publisher","first-page":"6942","DOI":"10.1097\/MS9.0000000000003857","article-title":"Datopotamab deruxtecan: a new era in targeted therapy for metastatic breast cancer","volume":"87","author":"Mobashir","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"2026091106322338900_ref28","first-page":"p195","volume-title":"WHO Drug Info","author":"Penpulimabum","year":"2021"},{"key":"2026091106322338900_ref29","volume-title":"US License Not Stated","author":"Penpulimab prescribing information","year":"2025"},{"key":"2026091106322338900_ref30","volume-title":"FDA Approves Penpulimab-Kcqx for Non-keratinizing Nasopharyngeal Carcinoma","year":"2025"},{"key":"2026091106322338900_ref31","first-page":"p203","volume-title":"WHO Drug Info","author":"Nipocalimabum","year":"2024"},{"key":"2026091106322338900_ref32","volume-title":"US License No. 1864","author":"Imaavy\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref33","doi-asserted-by":"publisher","first-page":"7891","DOI":"10.1097\/MS9.0000000000004103","article-title":"Nipocalimab: a significant milestone in the treatment of myasthenia gravis approved by the FDA","volume":"87","author":"Irfan","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"2026091106322338900_ref34","first-page":"p133","volume-title":"WHO Drug Info","author":"Telisotuzumabum vedotinum","year":"2017"},{"key":"2026091106322338900_ref35","volume-title":"US License No. 1889","author":"Emrelis\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s40265-025-02210-z","article-title":"Telisotuzumab Vedotin: First approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"2026091106322338900_ref37","first-page":"p717","volume-title":"WHO Drug Info","author":"Clesrovimabum","year":"2022"},{"key":"2026091106322338900_ref38","volume-title":"US License No. 0002","author":"Enflonsia\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref39","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40265-025-02224-7","article-title":"Clesrovimab: First approval.","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"2026091106322338900_ref40","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal fc receptor: biological consequences.","volume":"169","author":"Dall'Acqua","year":"2002","journal-title":"J Immunol"},{"key":"2026091106322338900_ref41","first-page":"p640","volume-title":"WHO Drug Info","author":"Garadacimabum","year":"2019"},{"key":"2026091106322338900_ref42","volume-title":"US License No. 1767","author":"Andembry\u00ae Prescribing Information","year":"2025"},{"key":"2026091106322338900_ref43","doi-asserted-by":"publisher","first-page":"10600280251405482","DOI":"10.1177\/10600280251405482","article-title":"Garadacimab-gxii-a novel prophylactic treatment for hereditary angioedema: a drug review","volume":"7","author":"Schindel","year":"2026","journal-title":"Ann Pharmacother"},{"key":"2026091106322338900_ref44","first-page":"p780","volume-title":"WHO Drug Info","author":"Linvoseltamabum","year":"2022"},{"key":"2026091106322338900_ref45","volume-title":"US License No. 1760","author":"Lynozyfic\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref46","doi-asserted-by":"publisher","first-page":"e70108","DOI":"10.1002\/cncr.70108","article-title":"FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma","volume":"131","author":"Lawrence","year":"2025","journal-title":"Cancer"},{"key":"2026091106322338900_ref47","first-page":"p726","volume-title":"WHO Drug Info","author":"Berahyaluronidasum alfa","year":"2023"},{"key":"2026091106322338900_ref48","volume-title":"US License No. 0002","author":"Keytruda QLEX\u2122 Prescribing information","year":"2025"},{"key":"2026091106322338900_ref49","doi-asserted-by":"publisher","first-page":"e184","DOI":"10.58347\/tml.2025.1741f","article-title":"In brief: Keytruda Qlex - a subcutaneous formulation of pembrolizumab","volume":"67","year":"2025","journal-title":"Med Lett Drugs Ther"},{"key":"2026091106322338900_ref50","doi-asserted-by":"publisher","first-page":"48","DOI":"10.21037\/jtd-2025-1951","article-title":"Comparison of subcutaneous checkpoint inhibitor immunotherapeutic agents","volume":"18","author":"Tanvetyanon","year":"2026","journal-title":"J Thorac Dis"},{"key":"2026091106322338900_ref51","first-page":"p809","volume-title":"WHO Drug Info","author":"Sibeprenlimabum","year":"2021"},{"key":"2026091106322338900_ref52","volume-title":"US License Not Provided","author":"Voyxact\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref53","article-title":"Otsuka receives FDA accelerated approval for VOYXACT\u00ae (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin a nephropathy (IgAN) at risk for disease progression","year":"2025","journal-title":"Otsuka press release"},{"key":"2026091106322338900_ref54","first-page":"p166","volume-title":"WHO Drug Info","author":"Lerodalcibepum","year":"2021"},{"key":"2026091106322338900_ref55","volume-title":"US License 2352","author":"Lerochol\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref56","volume-title":"U.S. Food and Drug Administration Approves LIB Therapeutics\u2019 LEROCHOL\u2122 (Lerodalcibep-Liga) for Adults with Elevated LDL Cholesterol","year":"2025"},{"key":"2026091106322338900_ref57","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1093\/eurheartj\/ehad596","article-title":"Long-term efficacy and safety of lerodalcibep in heterozygous familial hypercholesterolaemia: the LIBerate-HeFH trial","volume":"44","author":"Raal","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091106322338900_ref58","first-page":"p129","volume-title":"WHO Drug Info","author":"Depemokimabum","year":"2021"},{"key":"2026091106322338900_ref59","volume-title":"US License 1727","author":"Exdensur\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref60","volume-title":"Exdensur FDA Approval History","author":"Stewart"},{"key":"2026091106322338900_ref61","volume-title":"Manufactured by Janssen Biotech. License 1864","author":"Rybrevant Faspro\u2122 prescribing information"},{"key":"2026091106322338900_ref62","volume-title":"U.S. FDA Approval of RYBREVANT FASPRO\u2122 (Amivantamab and Hyaluronidase-Lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE\u00ae (Lazertinib),"},{"key":"2026091106322338900_ref63","volume-title":"WHO Drug Info","author":"Narsoplimabum","year":"2020"},{"key":"2026091106322338900_ref64","volume-title":"US License 2141","author":"Yartemlea\u00ae Prescribing information","year":"2025"},{"key":"2026091106322338900_ref65","volume-title":"FDA Approves Omeros\u2019 Yartemlea\u00ae - First and Only Therapy Indicated for TA-TMA"},{"key":"2026091106322338900_ref66","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1073\/pnas.63.1.78","article-title":"The covalent structure of an entire gamma G immunoglobulin molecule.","volume":"63","author":"Edelman","year":"1969","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026091106322338900_ref67","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0161-5890(93)90432-b","article-title":"A single amino acid substitution abolishes the heterogeneity of chimeric mouse\/human (IgG4) antibody","volume":"30","author":"Angal","year":"1993","journal-title":"Mol Immunol"},{"key":"2026091106322338900_ref68","doi-asserted-by":"publisher","first-page":"1779974","DOI":"10.1080\/19420862.2020.1779974","article-title":"Prevention of fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region","volume":"12","author":"Handlogten","year":"2020","journal-title":"MAbs"},{"key":"2026091106322338900_ref69","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"2026091106322338900_ref70","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4137\/CMC.S4434","article-title":"Ecallantide for the treatment of hereditary angiodema in adults","volume":"5","author":"Lunn","year":"2011","journal-title":"Clin Med Insights Cardiol"},{"key":"2026091106322338900_ref71","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003495-200161090-00007","article-title":"Gemtuzumab ozogamicin","volume":"61","author":"McGavin","year":"2001","journal-title":"Drugs"},{"key":"2026091106322338900_ref72","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NW2025-0117","article-title":"Cancer Throughlines: 25 years after first approval, ADCs continue to pick up steam","volume":"16","year":"2026","journal-title":"Cancer Discov"},{"key":"2026091106322338900_ref73","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/procel\/pwaf002","article-title":"The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts","volume":"16","author":"Liu","year":"2025","journal-title":"Protein Cell"},{"key":"2026091106322338900_ref74","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.3390\/pharmaceutics17091164","article-title":"Strategic and chemical advances in antibody-drug conjugates","volume":"17","author":"Alradwan","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026091106322338900_ref75","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/abt\/tbaf010","article-title":"A review of conjugation technologies for antibody drug conjugates","volume":"8","author":"Fan","year":"2025","journal-title":"Antib Ther"},{"key":"2026091106322338900_ref76","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.3390\/molecules26195847","article-title":"An insight into FDA approved antibody-drug conjugates for cancer therapy","volume":"26","author":"Tong","year":"2021","journal-title":"Molecules"},{"key":"2026091106322338900_ref77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026091106322338900_ref78","volume-title":"The ADC 2025 Landscape Review","author":"BEACON, by Hansonwade, London, UK"},{"key":"2026091106322338900_ref79","first-page":"p99","volume-title":"WHO Drug Info","author":"Gemtuzumabum ozogamicinum","year":"2017"},{"key":"2026091106322338900_ref80","first-page":"p52","volume-title":"WHO Drug Info","author":"Brentuximabum vedotinum","year":"2011"},{"key":"2026091106322338900_ref81","first-page":"p66","volume-title":"WHO International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for Radicals, Groups & Others. Comprehensive List","author":"Vedotinum","year":"2015"},{"key":"2026091106322338900_ref82","volume-title":"License 1853","author":"Adcetris\u00ae prescribing information"},{"key":"2026091106322338900_ref83","first-page":"p52","volume-title":"WHO Drug Info","author":"Trastuzumabum emtansinum","year":"2011"},{"key":"2026091106322338900_ref84","first-page":"p64","volume-title":"WHO International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for Radicals, Groups & Others. Comprehensive List","author":"Emtansinum","year":"2015"},{"key":"2026091106322338900_ref85","volume-title":"License 1048","author":"Kadcyla\u00ae prescribing information"},{"key":"2026091106322338900_ref86","first-page":"p257","volume-title":"WHO Drug Info","author":"Inotuzumabum ozogamicinum","year":"2005"},{"key":"2026091106322338900_ref87","volume-title":"License 003","author":"Besponza prescribing information"},{"key":"2026091106322338900_ref88","first-page":"p306","volume-title":"WHO Drug Info","author":"Polatuzumab vedotin","year":"2013"},{"key":"2026091106322338900_ref89","volume-title":"License 1048","author":"Polivy\u00ae prescribing information"},{"key":"2026091106322338900_ref90","first-page":"p87","volume-title":"WHO Drug Info","author":"Enfortumabum vedotinum","year":"2014"},{"key":"2026091106322338900_ref91","volume-title":"License 2124","author":"Padcev\u00ae prescribing information"},{"key":"2026091106322338900_ref92","first-page":"p562","volume-title":"WHO Drug Info","author":"Trastuzumabum deruxtecanum","year":"2017"},{"key":"2026091106322338900_ref93","volume-title":"License 2128","author":"Enhertu prescribing information"},{"key":"2026091106322338900_ref94","first-page":"p153","volume-title":"WHO Drug Info","author":"Sacituzumabum govitecanum","year":"2016"},{"key":"2026091106322338900_ref95","volume-title":"License 1737","author":"Trodelvy\u00ae prescribing information"},{"key":"2026091106322338900_ref96","first-page":"p431","volume-title":"WHO Drug Info","author":"Belantamabum mafodotinum","year":"2018"},{"key":"2026091106322338900_ref97","first-page":"p64","volume-title":"WHO International Nonproprietary Names (INN) for Pharmaceutical Substances: Names for Radicals, Groups & Others. Comprehensive List","author":"Mafodotinum","year":"2015"},{"key":"2026091106322338900_ref98","volume-title":"License 1727","author":"Blenrep\u00ae prescribing information"},{"key":"2026091106322338900_ref99","first-page":"p133","volume-title":"WHO Drug Info","author":"Loncastuximabum tesirinum","year":"2018"},{"key":"2026091106322338900_ref100","first-page":"p258","volume-title":"WHO Drug Info","author":"Rovalpituzumabum tesirinum","year":"2015"},{"key":"2026091106322338900_ref101","volume-title":"License 1727","author":"Zynlonta\u00ae prescribing information"},{"key":"2026091106322338900_ref102","first-page":"p159","volume-title":"WHO Drug Info","author":"Tisotumabum vedotinum"},{"key":"2026091106322338900_ref103","volume-title":"License Not Provided","author":"Tivdak\u00ae prescribing information"},{"key":"2026091106322338900_ref104","first-page":"p131","volume-title":"WHO Drug Info","author":"Mirvetuximabum soravtansinum","year":"2016"},{"key":"2026091106322338900_ref105","volume-title":"License Not Provided","author":"Elahere\u00ae prescribing information"},{"key":"2026091106322338900_ref106","volume-title":"License No. 2016","author":"Ajovy\u00ae prescribing information"},{"key":"2026091106322338900_ref107","volume-title":"License No. 1864","author":"Stelara\u00ae prescribing information"},{"key":"2026091106322338900_ref108","volume-title":"License No. 2097","author":"Vyepti\u00ae prescribing information"},{"key":"2026091106322338900_ref109","author":"Hemlibra\u00ae prescribing information"},{"key":"2026091106322338900_ref110","volume-title":"US License No. 1261","author":"Alhemo\u00ae Prescribing information","year":"2024"},{"key":"2026091106322338900_ref111","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","article-title":"Enhanced antibody half-life improves in vivo activity","volume":"28","author":"Zalevsky","year":"2010","journal-title":"Nat Biotechnol"},{"key":"2026091106322338900_ref112","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13036-025-00506-y","article-title":"Engineering FcRn binding kinetics dramatically extends antibody serum half-life and enhances therapeutic potential","volume":"19","author":"Ko","year":"2025","journal-title":"J Biol Eng"},{"key":"2026091106322338900_ref113","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1038\/s41467-024-46321-9","article-title":"Human IgG fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria","volume":"15","author":"Foss","year":"2007","journal-title":"Nat Commun"},{"key":"2026091106322338900_ref114","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/protein\/gzq009","article-title":"Reduced elimination of IgG antibodies by engineering the variable region","volume":"23","author":"Igawa","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"2026091106322338900_ref115","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/19420862.2017.1389355","article-title":"Changes in complementarity-determining regions significantly alter IgG binding to the neonatal fc receptor (FcRn) and pharmacokinetics","volume":"10","author":"Piche-Nicholas","year":"2018","journal-title":"MAbs"},{"key":"2026091106322338900_ref116","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"key":"2026091106322338900_ref117","volume-title":"Molecules with Extended Half-Lives, Compositions and Uses Thereof","author":"US7658921B2"},{"key":"2026091106322338900_ref118","volume-title":"Our Approach","author":"Spyre Therapeutics, Inc"},{"key":"2026091106322338900_ref119","author":"Apogee Therapeutics pipeline"},{"key":"2026091106322338900_ref120","doi-asserted-by":"publisher","first-page":"9604","DOI":"10.3390\/ijms23179604","article-title":"Monoclonal antibody engineering and design to modulate FcRn activities: a comprehensive review","volume":"23","author":"Ramdani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026091106322338900_ref121","doi-asserted-by":"publisher","first-page":"eabl8124","DOI":"10.1126\/scitranslmed.abl8124","article-title":"The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans","volume":"14","author":"Loo","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026091106322338900_ref122","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1208\/s12248-012-9369-y","article-title":"Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics","volume":"14","author":"Bumbaca","year":"2012","journal-title":"AAPS J"},{"key":"2026091106322338900_ref123","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s13238-017-0408-4","article-title":"Pharmacokinetics of monoclonal antibodies and fc-fusion proteins","volume":"9","author":"Liu","year":"2018","journal-title":"Protein Cell"},{"key":"2026091106322338900_ref124","doi-asserted-by":"publisher","first-page":"2040620719874728","DOI":"10.1177\/2040620719874728","article-title":"Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria","volume":"10","author":"Stern","year":"2019","journal-title":"Ther Adv Hematol"},{"key":"2026091106322338900_ref125","first-page":"p256","volume-title":"WHO Drug Info","author":"Sotrovimabum","year":"2021"},{"key":"2026091106322338900_ref126","volume-title":"Center for Drug Evaluation and Research (CDER) Memorandum","author":"Emergency Use Authorization (EUA) for Sotrovimab","year":"2026"},{"key":"2026091106322338900_ref127","volume-title":"Evusheld FDA Approval Status","author":"Stewart"},{"key":"2026091106322338900_ref128","doi-asserted-by":"publisher","first-page":"1283120","DOI":"10.3389\/fimmu.2023.1283120","article-title":"Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection","volume":"14","author":"Brady","year":"2023","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref129","volume-title":"US License No. 2059","author":"Beyfortus\u00ae Prescribing information","year":"2023"},{"key":"2026091106322338900_ref130","doi-asserted-by":"publisher","first-page":"11679","DOI":"10.3390\/ijms252111679","article-title":"Beyond recycling antibodies: Crovalimab\u2019s molecular design enables four-weekly subcutaneous injections for PNH treatment","volume":"25","author":"Sampei","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026091106322338900_ref131","volume-title":"US License No. 1048","author":"Piasky\u00ae Prescribing information","year":"2024"},{"key":"2026091106322338900_ref132","doi-asserted-by":"publisher","first-page":"115851","DOI":"10.1016\/j.biopha.2023.115851","article-title":"Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults","volume":"169","author":"Phuah","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"2026091106322338900_ref133","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/ACI.0000000000001112","article-title":"Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps","volume":"25","author":"Bernstein","year":"2025","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2026091106322338900_ref134","volume-title":"Depemokimab as an Extended Treatment Duration Biologic in Adults with Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) (ENDURA-2)"},{"key":"2026091106322338900_ref135","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/all.15262","article-title":"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study","volume":"77","author":"Alvarado","year":"2022","journal-title":"Allergy"},{"key":"2026091106322338900_ref136","volume-title":"A Phase 3 Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria (CSU) (EMBARQ-CSU2)","author":"NCT06455202"},{"key":"2026091106322338900_ref137","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1016\/j.jacc.2024.07.035","article-title":"Recaticimab monotherapy for nonfamilial hypercholesterolemia and mixed hyperlipemia: the phase 3 REMAIN-1 randomized trial","volume":"84","author":"Xu","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026091106322338900_ref138","volume-title":"Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered with Endovascular Therapy for Large Artery Occlusion (EAST-LDL)","author":"NCT07002476"},{"key":"2026091106322338900_ref139","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa2034031","article-title":"A monoclonal antibody for malaria prevention","volume":"385","author":"Gaudinski","year":"2021","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref140","volume-title":"Monoclonal Antibodies in Children with Severe Anaemia or Severe Malaria to Prevent Malaria after Hospital Discharge (L9LS-pd)","author":"NCT07082205"},{"key":"2026091106322338900_ref141","doi-asserted-by":"publisher","first-page":"e01020","DOI":"10.1128\/AAC.01020-16","article-title":"Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults","volume":"61","author":"Yu","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091106322338900_ref142","volume-title":"A Human Monoclonal Antibody against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2 (SAATELLITE-2)","author":"NCT05331885"},{"key":"2026091106322338900_ref143","doi-asserted-by":"publisher","first-page":"100545","DOI":"10.1016\/j.jacig.2025.100545","article-title":"In vitro potency and pharmacokinetics of APG777, a novel anti-IL-13 mAb","volume":"4","author":"Zhu","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"2026091106322338900_ref144","volume-title":"A Long-Term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis","author":"NCT07003425"},{"key":"2026091106322338900_ref145","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PLoS Med"},{"key":"2026091106322338900_ref146","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1002\/jcph.70060","article-title":"Pharmacokinetics analysis of serum and rectal tissue concentrations of a pair of anti-HIV monoclonal antibodies, VRC01 and VRC01LS, in adults without HIV","volume":"65","author":"Huang","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2026091106322338900_ref147","doi-asserted-by":"publisher","first-page":"e0127323","DOI":"10.1128\/aac.01273-23","article-title":"A phase 1 study in healthy volunteers to investigate the safety, tolerability, and pharmacokinetics of VIR-2482: a monoclonal antibody for the prevention of severe influenza A illness","volume":"68","author":"Plotnik","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026091106322338900_ref148","volume-title":"A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza a","author":"NCT05567783"},{"key":"2026091106322338900_ref149","volume-title":"EASL (European Association for the Study of the Liver)","author":"Wang","year":"2024"},{"key":"2026091106322338900_ref150","volume-title":"A Study to Evaluate Tobevibart+Elebsiran in Participants with Chronic HDV Infection Not Virologically Suppressed with Bulevirtide","author":"NCT07128550"},{"key":"2026091106322338900_ref151","volume-title":"3BNC117-LS (and 10\u20131074-LS) Clinical Development","author":"Caskey"},{"key":"2026091106322338900_ref152","volume-title":"Antiretrovirals Combined with Antibodies for HIV-1 Cure In Africa (ACACIA)","author":"NCT06205602"},{"key":"2026091106322338900_ref153","author":"Spyre Therapeutics, Inc Form 8-K","year":"2025"},{"key":"2026091106322338900_ref154","volume-title":"A Study of Long-Acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis (SKYLINE-UC)","author":"NCT07012395"},{"key":"2026091106322338900_ref155","author":"Vugmeyster","year":"2026"},{"key":"2026091106322338900_ref156","doi-asserted-by":"publisher","first-page":"i2015","DOI":"10.1093\/ecco-jcc\/jjae190.1271","article-title":"P1097. Phase 1\/2 study to assess safety, tolerability, and efficacy of XmAb942 (anti-TL1A) in healthy participants and participants with ulcerative colitis","volume":"19","author":"Hung","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2026091106322338900_ref157","volume-title":"Study of XmAb942 in Healthy Participants and Participants with Ulcerative Colitis","author":"NCT06619990"},{"key":"2026091106322338900_ref158","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1093\/cid\/ciaf265","article-title":"Safety and efficacy of pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic COVID-19: interim results from a phase 3 randomized clinical trial (CANOPY)","volume":"81","author":"Wolfe","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026091106322338900_ref159","doi-asserted-by":"publisher","first-page":"eadg2783","DOI":"10.1126\/scitranslmed.adg2783","article-title":"Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers","volume":"15","author":"Schmidt","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026091106322338900_ref160","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","article-title":"Living in LALA land? Forty years of attenuating fc effector functions","volume":"328","author":"Hale","year":"2024","journal-title":"Immunol Rev"},{"key":"2026091106322338900_ref161","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.7150\/thno.98178","article-title":"Trop2-targeted therapies in solid tumors: advances and future directions","volume":"14","author":"Liu","year":"2024","journal-title":"Theranostics"},{"key":"2026091106322338900_ref162","doi-asserted-by":"publisher","first-page":"117863","DOI":"10.1016\/j.ejmech.2025.117863","article-title":"Evolution of TROP2: biological insights and clinical applications","volume":"296","author":"Zhang","year":"2025","journal-title":"Eur J Med Chem"},{"key":"2026091106322338900_ref163","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3390\/cancers15061744","article-title":"Overview of Trop-2 in cancer: from pre-clinical studies to future directions in clinical settings","volume":"15","author":"Lombardi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091106322338900_ref164","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3892\/ol.2023.14114","article-title":"Immunohistochemical expression of TROP-2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer","volume":"26","author":"Abbas","year":"2023","journal-title":"Oncol Lett"},{"key":"2026091106322338900_ref165","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"2026091106322338900_ref166","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.3390\/cancers17071102","article-title":"Molecular subtypes and mechanisms of breast cancer: precision medicine approaches for targeted therapies","volume":"17","author":"Carvalho","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026091106322338900_ref167","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","article-title":"HER2-targeted therapies in cancer: a systematic review","volume":"12","author":"Zhu","year":"2024","journal-title":"Biomark Res"},{"key":"2026091106322338900_ref168","doi-asserted-by":"crossref","volume-title":"Surveillance, Epidemiology and End Results Program","author":"National Cancer Institute","DOI":"10.32388\/5OWTL5"},{"key":"2026091106322338900_ref169","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminoncol.2020.05.010","article-title":"Management of hormone receptor-positive, HER2-negative early breast cancer","volume":"47","author":"Walsh","year":"2020","journal-title":"Semin Oncol"},{"key":"2026091106322338900_ref170","volume-title":"World Cancer Research Fund","author":"Lung cancer statistics"},{"key":"2026091106322338900_ref171","author":"Special section: Lung cancer","year":"2023"},{"key":"2026091106322338900_ref172","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s13193-011-0108-0","article-title":"Targetable ``driver'' mutations in non-small cell lung cancer","volume":"2","author":"Vijayalakshmi","year":"2011","journal-title":"Indian J Surg Oncol"},{"key":"2026091106322338900_ref173","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cllc.2022.06.002","article-title":"Treatment considerations for patients with advanced squamous cell carcinoma of the lung","volume":"23","author":"Santos","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2026091106322338900_ref174","doi-asserted-by":"publisher","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"2026091106322338900_ref175","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.resinv.2025.04.021","article-title":"Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations","volume":"63","author":"Miyata","year":"2025","journal-title":"Respir Investig"},{"key":"2026091106322338900_ref176","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026091106322338900_ref177","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15698\/cst2025.08.311","article-title":"Datopotamab deruxtecan induces hallmarks of immunogenic cell death","volume":"9","author":"Forveille","year":"2025","journal-title":"Cell Stress"},{"key":"2026091106322338900_ref178","volume-title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants with Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated with One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","author":"NCT05104866"},{"key":"2026091106322338900_ref179","doi-asserted-by":"publisher","first-page":"S0923-7534(25)06337","DOI":"10.1016\/j.annonc.2025.12.017","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","volume":"23","author":"Pistilli","year":"2025","journal-title":"Ann Oncol"},{"key":"2026091106322338900_ref180","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA approval summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026091106322338900_ref181","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091106322338900_ref182","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026091106322338900_ref183","volume-title":"FDA Grants Accelerated Approval to Datopotamab Deruxtecan-Dlnk for EGFR-Mutated Non-small Cell Lung Cancer"},{"key":"2026091106322338900_ref184","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1158\/1078-0432.CCR-21-1560","article-title":"Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan with concomitant ritonavir or itraconazole in patients with HER2-expressing advanced solid tumors","volume":"27","author":"Takahashi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026091106322338900_ref185","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"2026091106322338900_ref186","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/cancers17091493","article-title":"Targeting c-MEt alterations in cancer: a review of genetic drivers and therapeutic implications","volume":"17","author":"Ji","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026091106322338900_ref187","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.2340\/1651-226X.2025.44344","article-title":"Prevalence, molecular characterization, and prognosis of c-met protein overexpression in a real-world cohort of patients with non-squamous non-small cell lung cancer","volume":"64","author":"Bar","year":"2025","journal-title":"Acta Oncol"},{"key":"2026091106322338900_ref188","doi-asserted-by":"publisher","first-page":"207","DOI":"10.3390\/cancers18020207","article-title":"Targeting mesenchymal-epidermal transition (MET) aberrations in non-small cell lung cancer: current challenges and therapeutic advances","volume":"18","author":"Deng","year":"2026","journal-title":"Cancers (Basel)"},{"key":"2026091106322338900_ref189","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jtho.2025.05.012","article-title":"Amivantamab in participants with advanced NSCLC and MET exon 14 skipping mutations: final results from the CHRYSALIS study","volume":"20","author":"Krebs","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026091106322338900_ref190","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5582\/ddt.2025.01058","article-title":"Telisotuzumab vedotin: the first-in-class c-met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)","volume":"19","author":"Zhao","year":"2025","journal-title":"Drug Discov Ther"},{"key":"2026091106322338900_ref191","volume-title":"Roche Receives FDA Approval for the VENTANA MET (SP44) RxDx Assay as the First Companion Diagnostic to Identify Non-squamous Non-small Cell Lung Cancer Patients Eligible for Treatment with Emrelis"},{"key":"2026091106322338900_ref192","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-met antibody-drug conjugate that targets both MET-amplified and c-met-overexpressing Tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026091106322338900_ref193","volume-title":"Study of Telisotuzumab Vedotin (ABBV-399) in Participants with Previously Treated c-Met+ Non-Small Cell Lung Cancer","author":"NCT03539536"},{"key":"2026091106322338900_ref194","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026091106322338900_ref195","volume-title":"A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants with Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","author":"NCT04928846"},{"key":"2026091106322338900_ref196","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/jcph.116","article-title":"CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies","volume":"53","author":"Han","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"2026091106322338900_ref197","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/jcph.70108","article-title":"Assessment of telisotuzumab vedotin drug-drug interaction potential using physiologically-based pharmacokinetic modeling and simulations","volume":"65","author":"Riad","year":"2025","journal-title":"J Clin Pharmacol"},{"key":"2026091106322338900_ref198","doi-asserted-by":"publisher","first-page":"e70219","DOI":"10.1002\/psp4.70219","article-title":"Population pharmacokinetics and exposure-response analyses for telisotuzumab vedotin in patients with c-met protein overexpressing tumors","volume":"15","author":"Babel","year":"2026","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2026091106322338900_ref199","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"2026091106322338900_ref200","doi-asserted-by":"publisher","first-page":"1470381","DOI":"10.3389\/fmed.2024.1470381","article-title":"Eosinophils: old cells, new directions","volume":"11","author":"Sanchez Santos","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2026091106322338900_ref201","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol Int"},{"key":"2026091106322338900_ref202","volume-title":"US License No. 1727","author":"Nucala\u00ae prescribing information","year":"2025"},{"key":"2026091106322338900_ref203","volume-title":"US License No. 2016","author":"Cinqair\u00ae prescribing information","year":"2016"},{"key":"2026091106322338900_ref204","volume-title":"US License No. 2059","author":"Fasenra\u00ae prescribing information","year":"2024"},{"key":"2026091106322338900_ref205","doi-asserted-by":"publisher","first-page":"5698212","DOI":"10.1155\/2018\/5698212","article-title":"Anti-IL-5 and IL-5R\u03b1: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","volume":"2018","author":"Bagnasco","year":"2018","journal-title":"Biomed Res Int"},{"key":"2026091106322338900_ref206","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.medj.2024.10.022","article-title":"Depemokimab, the first ultra-long-acting anti-IL-5 monoclonal antibody for severe eosinophilic asthma","volume":"5","author":"Nolasco","year":"2024","journal-title":"Med"},{"key":"2026091106322338900_ref207","doi-asserted-by":"publisher","first-page":"384","DOI":"10.3390\/cells13050384","article-title":"Eosinophilic asthma: pathophysiology and therapeutic horizons","volume":"13","author":"Hussain","year":"2024","journal-title":"Cells"},{"key":"2026091106322338900_ref208","volume-title":"World Health Organization","author":"Asthma"},{"key":"2026091106322338900_ref209","doi-asserted-by":"publisher","volume-title":"Prev Chronic Dis","author":"Pate","DOI":"10.5888\/pcd21.240005"},{"key":"2026091106322338900_ref210","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","article-title":"Eosinophils in asthma phenotypes: perpetrators or guilty by association?","volume":"13","author":"Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026091106322338900_ref211","doi-asserted-by":"publisher","first-page":"18","DOI":"10.15406\/jlprr.2020.07.00223","article-title":"Neutrophilic asthma: a complex phenotype of severe asthma","volume":"7","author":"Syabbalo","year":"2020","journal-title":"J Lung Pulm Respir Res"},{"key":"2026091106322338900_ref212","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026091106322338900_ref213","volume-title":"Exdensur (Depemokimab) Approved in the UK for Treatment of Asthma with Type 2 Inflammation and Chronic Rhinosinusitis with Nasal Polyps. 12\/15\/25"},{"key":"2026091106322338900_ref214","volume-title":"GSK Wins EU Approval for Exdensur in Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps. 2\/17\/26"},{"key":"2026091106322338900_ref215","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026091106322338900_ref216","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref217","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s12325-025-03457-4","article-title":"Safety and tolerability of twice-yearly depemokimab in patients with asthma and chronic rhinosinusitis with nasal polyps: pooled results from SWIFT-1\/\u22122 and ANCHOR-1\/\u22122","volume":"43","author":"Jackson","year":"2026","journal-title":"Adv Ther"},{"key":"2026091106322338900_ref218","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"key":"2026091106322338900_ref219","doi-asserted-by":"publisher","first-page":"uqaf003","DOI":"10.1093\/femsml\/uqaf003","article-title":"Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned","volume":"6","author":"Br\u00fcssow","year":"2025","journal-title":"Microlife"},{"key":"2026091106322338900_ref220","doi-asserted-by":"publisher","first-page":"1132740","DOI":"10.3389\/fped.2023.1132740","article-title":"The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: a systematic review and meta-analysis","volume":"11","author":"Turalde-Mapili","year":"2023","journal-title":"Front Pediatr"},{"key":"2026091106322338900_ref221","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1542\/peds.99.3.454","article-title":"Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: respiratory syncytial virus immune globulin study group","volume":"99","author":"Rodriguez","year":"1997","journal-title":"Pediatrics"},{"key":"2026091106322338900_ref222","doi-asserted-by":"publisher","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","article-title":"Palivizumab","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"2026091106322338900_ref223","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.18749.1","article-title":"The long road to protect infants against severe RSV lower respiratory tract illness","volume":"8","author":"Jares Baglivo","year":"2019","journal-title":"F1000Res"},{"key":"2026091106322338900_ref224","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref225","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref226","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1038\/s41467-019-12137-1","article-title":"A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein","volume":"10","author":"Tang","year":"2019","journal-title":"Nat Commun"},{"key":"2026091106322338900_ref227","doi-asserted-by":"publisher","first-page":"e478","DOI":"10.1093\/infdis\/jiae581","article-title":"A phase 1b\/2a trial of a half-life extended respiratory syncytial virus neutralizing antibody, clesrovimab, in healthy preterm and full-term infants","volume":"231","author":"Madhi","year":"2025","journal-title":"J Infect Dis"},{"key":"2026091106322338900_ref228","doi-asserted-by":"publisher","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci Transl Med"},{"key":"2026091106322338900_ref229","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3389\/fimmu.2019.00548","article-title":"Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease","volume":"10","author":"Erp","year":"2019","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref230","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa2502984","article-title":"Clesrovimab for prevention of RSV disease in healthy infants","volume":"393","author":"Zar","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref231","volume-title":"Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004) (CLEVER)","author":"NCT04767373"},{"key":"2026091106322338900_ref232","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMc2506107","article-title":"Clesrovimab in infants and children at increased risk for severe RSV disease","volume":"393","author":"Zar","year":"2025","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref233","author":"NCT04938830"},{"key":"2026091106322338900_ref234","doi-asserted-by":"publisher","author":"Simonich","DOI":"10.64898\/2026.02.12.705519"},{"key":"2026091106322338900_ref235","doi-asserted-by":"publisher","first-page":"e488","DOI":"10.1093\/infdis\/jiae582","article-title":"Development of high-titer antidrug antibodies in a phase 1b\/2a infant clesrovimab trial are associated with RSV exposure beyond day 150","volume":"231","author":"Thambi","year":"2025","journal-title":"J Infect Dis"},{"key":"2026091106322338900_ref236","doi-asserted-by":"publisher","first-page":"201044","DOI":"10.1016\/j.omton.2025.201044","article-title":"Targeting BCMA in multiple myeloma: a comprehensive review of immunotherapeutic strategies and clinical outcomes","volume":"33","author":"Chan","year":"2025","journal-title":"Mol Ther Oncol"},{"key":"2026091106322338900_ref237","doi-asserted-by":"publisher","first-page":"25764","DOI":"10.18632\/oncotarget.25359","article-title":"Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma","volume":"9","author":"Bu","year":"2018","journal-title":"Oncotarget"},{"key":"2026091106322338900_ref238","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","article-title":"\u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"2026091106322338900_ref239","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.3390\/cancers15061791","article-title":"The BAFF-APRIL system in cancer","volume":"15","author":"Ullah","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026091106322338900_ref240","doi-asserted-by":"publisher","first-page":"16727","DOI":"10.1074\/jbc.M312316200","article-title":"Engineering an APRIL-specific B cell maturation antigen","volume":"279","author":"Patel","year":"2004","journal-title":"J Biol Chem"},{"key":"2026091106322338900_ref241","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"2026091106322338900_ref242","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","article-title":"Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density","volume":"11","author":"Niwa","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2026091106322338900_ref243","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/s41591-025-04170-z","article-title":"BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial","volume":"32","author":"Fedak","year":"2026","journal-title":"Nat Med"},{"key":"2026091106322338900_ref244","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/medsci9010003","article-title":"Epidemiology, staging, and management of multiple myeloma","volume":"9","author":"Padala","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"2026091106322338900_ref245","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11899-020-00570-9","article-title":"Supportive care in multiple myeloma","volume":"15","author":"Guzdar","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"2026091106322338900_ref246","doi-asserted-by":"publisher","first-page":"170","DOI":"10.6004\/jnccn.2007.0017","article-title":"Multiple myeloma: most common end-organ damage and management","volume":"5","author":"Hussein","year":"2007","journal-title":"J Natl Compr Cancer Netw"},{"key":"2026091106322338900_ref247","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40265-015-0536-1","article-title":"First global approval","volume":"76","author":"Daratumumab","year":"2016","journal-title":"Drugs"},{"key":"2026091106322338900_ref248","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.7150\/ijbs.68148","article-title":"Regulation of CD38 on multiple myeloma and NK cells by monoclonal antibodies","volume":"18","author":"Wu","year":"2022","journal-title":"Int J Biol Sci"},{"key":"2026091106322338900_ref249","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11899-022-00682-4","article-title":"The role of belantamab mafodotin, selinexor, and melflufen in multiple myeloma","volume":"17","author":"McCurdy","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"2026091106322338900_ref250","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/ejh.14121","article-title":"Teclistamab-cqyv in multiple myeloma","volume":"112","author":"Martino","year":"2024","journal-title":"Eur J Haematol"},{"key":"2026091106322338900_ref251","doi-asserted-by":"publisher","first-page":"20363613231207483","DOI":"10.1177\/20363613231207483","article-title":"Elrexfio\u2122 (elranatamab-bcmm): the game-changer in treatment of multiple myeloma","volume":"15","author":"Rais","year":"2023","journal-title":"Rare Tumors"},{"key":"2026091106322338900_ref252","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40265-025-02207-8","article-title":"First approval","volume":"85","author":"Linvoseltamab","year":"2025","journal-title":"Drugs"},{"key":"2026091106322338900_ref253","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/10600280241271192","article-title":"Targeting GPRC5D with talquetamab: a new frontier in bispecific antibody therapy for relapsed\/refractory multiple myeloma","volume":"59","author":"Shaver","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026091106322338900_ref254","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"key":"2026091106322338900_ref255","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1080\/19420862.2016.1160192","article-title":"Development of purification processes for fully human bispecific antibodies based upon modification of protein a binding avidity","volume":"8","author":"Tustian","year":"2016","journal-title":"MAbs"},{"key":"2026091106322338900_ref256","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses","volume":"26","author":"Lee","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026091106322338900_ref257","volume-title":"Phase 1\/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma","author":"NCT03761108"},{"key":"2026091106322338900_ref258","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"key":"2026091106322338900_ref259","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/embo-reports\/kve198","article-title":"Biologically active APRIL is secreted following intracellular processing in the Golgi apparatus by furin convertase","volume":"2","author":"L\u00f3pez-Fraga","year":"2001","journal-title":"EMBO Rep"},{"key":"2026091106322338900_ref260","doi-asserted-by":"publisher","first-page":"7218","DOI":"10.1074\/jbc.M411714200","article-title":"Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding","volume":"280","author":"Hymowitz","year":"2005","journal-title":"J Biol Chem"},{"key":"2026091106322338900_ref261","doi-asserted-by":"publisher","first-page":"6927","DOI":"10.3390\/jcm12216927","article-title":"A PRoliferation-inducing ligand (APRIL) in the pathogenesis of immunoglobulin a nephropathy: a review of the evidence","volume":"12","author":"Mathur","year":"2023","journal-title":"J Clin Med"},{"key":"2026091106322338900_ref262","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"key":"2026091106322338900_ref263","doi-asserted-by":"publisher","first-page":"1346769","DOI":"10.3389\/fneph.2023.1346769","article-title":"The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies","volume":"3","author":"Cheung","year":"2024","journal-title":"Front Nephrol"},{"key":"2026091106322338900_ref264","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.34067\/KID.0000000000000165","article-title":"Global incidence of IgA nephropathy by race and ethnicity: a systematic review","volume":"4","author":"Kiryluk","year":"2023","journal-title":"Kidney360"},{"key":"2026091106322338900_ref265","doi-asserted-by":"publisher","first-page":"ii26","DOI":"10.1093\/ckj\/sfaf322","article-title":"Targeting B cells in IgA nephropathy: from pathogenic insight to therapeutic horizon","volume":"18","author":"Roberts","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026091106322338900_ref266","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"2026091106322338900_ref267","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3390\/jcm11102810","article-title":"New treatment strategies for IgA nephropathy: targeting plasma cells as the main source of pathogenic antibodies","volume":"11","author":"Maixnerova","year":"2022","journal-title":"J Clin Med"},{"key":"2026091106322338900_ref268","doi-asserted-by":"publisher","first-page":"ii9","DOI":"10.1093\/ckj\/sfad200","article-title":"The contribution of a proliferation-inducing ligand (APRIL) and other TNF superfamily members in pathogenesis and progression of IgA nephropathy","volume":"16","author":"Yeo","year":"2023","journal-title":"Clin Kidney J"},{"key":"2026091106322338900_ref269","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1016\/j.ekir.2025.09.031","article-title":"Evaluating sibeprenlimab in IgA nephropathy - rationale and baseline data from the VISIONARY trial","volume":"10","author":"Perkovic","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026091106322338900_ref270","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2512133","article-title":"Sibeprenlimab in IgA nephropathy - interim analysis of a phase 3 trial","volume":"394","author":"Perkovic","year":"2026","journal-title":"N Engl J Med"},{"key":"2026091106322338900_ref271","volume-title":"Trial of Sibeprenlimab in the Treatment of a Nephropathy (IgAN)","author":"NCT05248646"},{"key":"2026091106322338900_ref272","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026091106322338900_ref273","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ekir.2022.01.1073","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of VIS649 (sibeprenlimab), an APRIL-neutralizing IgG2 monoclonal antibody, in healthy volunteers","volume":"7","author":"Mathur","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026091106322338900_ref274","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.kint.2019.01.031","article-title":"A PRoliferation inducing ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy","volume":"96","author":"Myette","year":"2019","journal-title":"Kidney Int"},{"key":"2026091106322338900_ref275","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/cpdd.1316","article-title":"Safety, pharmacokinetics, and pharmacodynamics of subcutaneous sibeprenlimab in healthy participants","volume":"12","author":"Zhang","year":"2023","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026091106322338900_ref276","doi-asserted-by":"publisher","first-page":"102160","DOI":"10.1016\/j.rpth.2023.102160","article-title":"New insight into the traditional model of the coagulation cascade and its regulation: illustrated review of a three-dimensional view","volume":"7","author":"Troisi","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026091106322338900_ref277","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026091106322338900_ref278","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/MOH.0000000000000603","article-title":"The rebirth of the contact pathway: a new therapeutic target","volume":"27","author":"Srivastava","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"2026091106322338900_ref279","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems: pathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026091106322338900_ref280","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3390\/biom14101298","article-title":"Unveiling the complexities of hereditary angioedema","volume":"14","author":"Tutunaru","year":"2024","journal-title":"Biomolecules"},{"key":"2026091106322338900_ref281","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.alit.2023.04.004","article-title":"Biochemistry, molecular genetics, and clinical aspects of hereditary angioedema with and without C1 inhibitor deficiency","volume":"72","author":"Miyata","year":"2023","journal-title":"Allergol Int"},{"key":"2026091106322338900_ref282","doi-asserted-by":"publisher","first-page":"1039765","DOI":"10.3389\/fimmu.2022.1039765","article-title":"Distinction of early complement classical and lectin pathway activation via quantification of C1s\/C1-INH and MASP-1\/C1-INH complexes using novel ELISAs","volume":"13","author":"Hurler","year":"2022","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref283","doi-asserted-by":"publisher","first-page":"102653","DOI":"10.1016\/j.coi.2025.102653","article-title":"C1 inhibitor: from complement system to bradykinin angioedema","volume":"97","author":"Defendi","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"2026091106322338900_ref284","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.imbio.2006.10.003","article-title":"C1 inhibitor: biologic activities that are independent of protease inhibition","volume":"212","author":"Davis","year":"2007","journal-title":"Immunobiology"},{"key":"2026091106322338900_ref285","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s12016-018-8684-1","article-title":"Update on the use of C1-esterase inhibitor replacement therapy in the acute and prophylactic treatment of hereditary angioedema","volume":"56","author":"Henry Li","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026091106322338900_ref286","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2147\/JBM.S9576","article-title":"Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety","volume":"1","author":"Lunn","year":"2010","journal-title":"J Blood Med"},{"key":"2026091106322338900_ref287","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1016\/j.bbamcr.2017.07.009","article-title":"The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. Biochim Biophys Acta Mol","volume":"1864","author":"Weidmann","year":"2017","journal-title":"Cell Res"},{"key":"2026091106322338900_ref288","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/MS9.0000000000004452","article-title":"Novel drug approval by the FDA: Ekterly (Sebetralstat), oral plasma kallikrein inhibitor for treating acute attacks of hereditary angioedema.","volume":"88","author":"Gulalai","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"2026091106322338900_ref289","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40265-025-02257-y","article-title":"Donidalorsen: First approval","volume":"86","author":"Syed","year":"2026","journal-title":"Drugs"},{"key":"2026091106322338900_ref290","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.str.2024.07.001","article-title":"Structural basis for the inhibition of \u03b2FXIIa by garadacimab","volume":"32","author":"Drulyte","year":"2024","journal-title":"Structure"},{"key":"2026091106322338900_ref291","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"2026091106322338900_ref292","volume-title":"CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks = VANGUARD","author":"NCT04656418"},{"key":"2026091106322338900_ref293","doi-asserted-by":"publisher","first-page":"710390","DOI":"10.3389\/fncel.2021.710390","article-title":"Interaction between the complement system and infectious agents \u2013 a potential mechanistic link to neurodegeneration and dementia","volume":"15","author":"Shinjyo","year":"2021","journal-title":"Front Cell Neurosci"},{"key":"2026091106322338900_ref294","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"2026091106322338900_ref295","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.str.2016.12.014","article-title":"Flexibility in mannan-binding lectin-associated serine proteases-1 and -2 provides insight on lectin pathway activation","volume":"25","author":"Nan","year":"2017","journal-title":"Structure"},{"key":"2026091106322338900_ref296","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1096\/fj.201601306R","article-title":"Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and\/or C2","volume":"31","author":"Yaseen","year":"2017","journal-title":"FASEB J"},{"key":"2026091106322338900_ref297","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/jth.13208","article-title":"The lectin complement pathway serine proteases (MASPs) represent a possible crossroad between the coagulation and complement systems in thromboinflammation","volume":"14","author":"Kozarcanin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2026091106322338900_ref298","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1002\/ajh.26872","article-title":"Reeling in complement in transplant-associated thrombotic microangiopathy: You're going to need a bigger boat","volume":"98","author":"Jodele","year":"2023","journal-title":"Am J Hematol"},{"key":"2026091106322338900_ref299","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-0-387-78580-6_1","article-title":"Principles and overview of allogeneic hematopoietic stem cell transplantation","volume":"144","author":"Giralt","year":"2009","journal-title":"Cancer Treat Res"},{"key":"2026091106322338900_ref300","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1182\/hematology.2021000258","article-title":"Increasing access to allogeneic hematopoietic cell transplant: An international perspective","volume":"2021","author":"Rocha","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026091106322338900_ref301","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1182\/blood.2025028390","article-title":"High incidence of severe TA-TMA increases mortality in adult allogeneic transplant recipients: a prospective MIDAS consortium study","volume":"146","author":"Vasu","year":"2025","journal-title":"Blood"},{"key":"2026091106322338900_ref302","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3389\/fped.2019.00133","article-title":"Transplant-associated thrombotic microangiopathy in pediatric hematopoietic cell transplant recipients: a practical approach to diagnosis and management","volume":"7","author":"Dvorak","year":"2019","journal-title":"Front Pediatr"},{"key":"2026091106322338900_ref303","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/bloodadvances.2025017540","article-title":"Survival in adults with high-risk TA-TMA: a comparative analysis of narsoplimab vs supportive care","volume":"10","author":"Matsui","year":"2026","journal-title":"Blood Adv"},{"key":"2026091106322338900_ref304","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/s41409-025-02595-1","article-title":"Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)","volume":"60","author":"Chumnumsiriwath","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026091106322338900_ref305","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/cei.13497","article-title":"MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab","volume":"203","author":"Elhadad","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"2026091106322338900_ref306","doi-asserted-by":"publisher","first-page":"1297352","DOI":"10.3389\/fimmu.2023.1297352","article-title":"Development and characterization of narsoplimab, a selective MASP-2 inhibitor, for the treatment of lectin-pathway\u2013mediated disorders","volume":"14","author":"Dudler","year":"2023","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref307","doi-asserted-by":"publisher","first-page":"e623","DOI":"10.1371\/journal.pone.0000623","article-title":"Simultaneous activation of complement and coagulation by MBL-associated serine protease 2","volume":"2","author":"Krarup","year":"2007","journal-title":"PLoS One"},{"key":"2026091106322338900_ref308","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","article-title":"Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience","volume":"59","author":"Castelli","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"2026091106322338900_ref309","volume-title":"Safety and Efficacy Study of OMS721 in Patients with Thrombotic Microangiopathies","author":"NCT02222545"},{"key":"2026091106322338900_ref310","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/JCO.21.02389","article-title":"Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy","volume":"40","author":"Khaled","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026091106322338900_ref311","volume-title":"Single Patient Expanded Access Treatment Plan for the Investigational Product Narsoplimab","author":"NCT04247906"},{"key":"2026091106322338900_ref312","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin Transl Sci"},{"key":"2026091106322338900_ref313","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","article-title":"The therapeutic age of the neonatal fc receptor","volume":"23","author":"Pyzik","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"2026091106322338900_ref314","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40259-025-00708-2","article-title":"Targeting the neonatal fc receptor in autoimmune diseases: pipeline and progress","volume":"39","author":"Gj\u00f8lberg","year":"2025","journal-title":"BioDrugs"},{"key":"2026091106322338900_ref315","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jaci.2022.05.023","article-title":"Comprehensive overview of autoantibody isotype and subclass distribution","volume":"150","author":"Volkov","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026091106322338900_ref316","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.3390\/ijms22115755","article-title":"Fc-receptor targeted therapies for the treatment of myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026091106322338900_ref317","doi-asserted-by":"publisher","first-page":"1756286420986747","DOI":"10.1177\/1756286420986747","article-title":"VNTR2\/VNTR3 genotype in the FCGRT gene is associated with reduced effectiveness of intravenous immunoglobulin in patients with myasthenia gravis","volume":"14","author":"Su","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2026091106322338900_ref318","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: First approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"2026091106322338900_ref319","first-page":"516","volume-title":"WHO Drug Info","author":"Efgartigimodum alfa","year":"2017"},{"key":"2026091106322338900_ref320","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/1750743X.2025.2491295","article-title":"Rozanolixizumab for myasthenia gravis: a breakthrough treatment and future prospects","volume":"17","author":"Matic","year":"2025","journal-title":"Immunotherapy"},{"key":"2026091106322338900_ref321","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/ijms22063048","article-title":"In translation: FcRn across the therapeutic spectrum","volume":"22","author":"Qi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026091106322338900_ref322","doi-asserted-by":"publisher","first-page":"eaax9586","DOI":"10.1126\/sciadv.aax9586","article-title":"Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex-mediated immune responses","volume":"5","author":"Blumberg","year":"2019","journal-title":"Sci Adv"},{"key":"2026091106322338900_ref323","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/19420862.2025.2461191","article-title":"Nipocalimab, an immunoselective FcRn blocker that lowers IgG and has unique molecular properties","volume":"17","author":"Seth","year":"2025","journal-title":"MAbs"},{"key":"2026091106322338900_ref324","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1474-4422(24)00498-8","article-title":"Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"24","author":"Antozzi","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026091106322338900_ref325","volume-title":"A Study of Nipocalimab Administered to Adults with Generalized Myasthenia Gravis","author":"NCT04951622"},{"key":"2026091106322338900_ref326","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"2026091106322338900_ref327","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","article-title":"Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production","volume":"170","author":"Brown","year":"2003","journal-title":"J Immunol"},{"key":"2026091106322338900_ref328","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-004-0593-x","article-title":"Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy","volume":"54","author":"Blank","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"2026091106322338900_ref329","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.str.2017.06.011","article-title":"Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1\/PD-L2","volume":"25","author":"Zak","year":"2017","journal-title":"Structure"},{"key":"2026091106322338900_ref330","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-014-0314-5","article-title":"Pembrolizumab: First global approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"key":"2026091106322338900_ref331","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2015-042","article-title":"Nivolumab approved for lung cancer","volume":"5","year":"2015","journal-title":"Cancer Discov"},{"key":"2026091106322338900_ref332","volume-title":"China\u2019s 20th PD-(L)1 Drug. Oncology Online","author":"Plieth"},{"key":"2026091106322338900_ref333","doi-asserted-by":"publisher","first-page":"1116143","DOI":"10.3389\/fmicb.2023.1116143","article-title":"The role of Epstein-Barr virus in nasopharyngeal carcinoma","volume":"14","author":"Su","year":"2023","journal-title":"Front Microbiol"},{"key":"2026091106322338900_ref334","doi-asserted-by":"publisher","first-page":"1212813","DOI":"10.3389\/fphar.2023.1212813","article-title":"Anti-PD-1\/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov","volume":"14","author":"Dai","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026091106322338900_ref335","volume-title":"US License No. 2023","author":"Loqtorzi\u2122 Prescribing information","year":"2023"},{"key":"2026091106322338900_ref336","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026091106322338900_ref337","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","article-title":"First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"2026091106322338900_ref338","doi-asserted-by":"publisher","first-page":"924542","DOI":"10.3389\/fimmu.2022.924542","article-title":"Penpulimab, an fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref339","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"2026091106322338900_ref340","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fc\u03b3Rs modulate the anti-tumor activity of antibodies targeting the PD-1\/PD-L1 Axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"2026091106322338900_ref341","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fimmu.2019.00292","article-title":"Fc\u03b3R-binding is an important functional attribute for immune checkpoint antibodies in cancer immunotherapy","volume":"10","author":"Chen","year":"2019","journal-title":"Front Immunol"},{"key":"2026091106322338900_ref342","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1177\/10600280251391430","article-title":"Toripalimab and penpulimab: targeting PD-1 in recurrent or metastatic nasopharyngeal carcinoma","volume":"60","author":"Hockett","year":"2025","journal-title":"Ann Pharmacother"},{"key":"2026091106322338900_ref343","volume-title":"A Study of Penpulimab (AK105) in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma","author":"NCT04974398"},{"key":"2026091106322338900_ref344","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","article-title":"Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026091106322338900_ref345","volume-title":"A Study of Anti-PD-1 AK105 in Patients with Metastatic Nasopharyngeal Carcinoma","author":"NCT03866967"},{"key":"2026091106322338900_ref346","volume-title":"Top 10 Drugs with Patents Due to Expire in the Next Five Years","author":"Burke"},{"key":"2026091106322338900_ref347","volume-title":"Merck Announces Fourth-Quarter and Full-Year 2024 Financial Results","year":"2025"},{"key":"2026091106322338900_ref348","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE\u00ae drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"Locke","year":"2019","journal-title":"Drug Deliv"},{"key":"2026091106322338900_ref349","doi-asserted-by":"publisher","first-page":"115709","DOI":"10.1016\/j.ejca.2025.115709","article-title":"Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: the phase 1 study 3475A-C18","volume":"230","author":"Cohen","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026091106322338900_ref350","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s13555-025-01507-x","article-title":"The safety, tolerability, and pharmacokinetics of ALT-BB4 (a novel recombinant hyaluronidase): a randomized, double-blinded, placebo-controlled, phase 1 study in healthy volunteers","volume":"15","author":"Lee","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026091106322338900_ref351","volume-title":"Hybrozyme\u2122 Technology. Alteogen"},{"key":"2026091106322338900_ref352","volume-title":"Alteogen Modifies License Agreement with MSD for Exclusive Rights to ALT-B4","author":"Lee","year":"2024"},{"key":"2026091106322338900_ref353","volume-title":"Berahyaluronidase Alfa USAN MN-90 1"},{"key":"2026091106322338900_ref354","volume-title":"Licenses 1713 and 2187","author":"Opdivo Qvantig\u00ae prescribing information","year":"2024"},{"key":"2026091106322338900_ref355","volume-title":"License 1048","author":"Tecentriq Hybreza\u00ae prescribing information","year":"2024"},{"key":"2026091106322338900_ref356","doi-asserted-by":"publisher","first-page":"101314","DOI":"10.1016\/j.ajpc.2025.101314","article-title":"The discovery of PCSK9 as a pivotal point in the prevention of cardiovascular disease","volume":"24","author":"Razavi","year":"2025","journal-title":"Am J Prev Cardiol"},{"key":"2026091106322338900_ref357","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","article-title":"Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside","volume":"9","author":"Bao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026091106322338900_ref358","doi-asserted-by":"publisher","first-page":"311","DOI":"10.31083\/j.rcm2411311","article-title":"Familial hypercholesterolemia: from clinical suspicion to novel treatments","volume":"24","author":"Mirzai","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"2026091106322338900_ref359","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/aje\/kwh236","article-title":"Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review","volume":"160","author":"Austin","year":"2004","journal-title":"Am J Epidemiol"},{"key":"2026091106322338900_ref360","doi-asserted-by":"publisher","first-page":"26753","DOI":"10.1038\/s41598-025-12432-6","article-title":"Gain of function variants in PCSK9 gene in high risk patients after myocardial infarction with increased lipoprotein (a) values and treated with statins","volume":"15","author":"Ugov\u0161ek","year":"2025","journal-title":"Sci Rep"},{"key":"2026091106322338900_ref361","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/protein\/gzq097","article-title":"Adnectins: engineered target-binding protein therapeutics","volume":"24","author":"Lipovsek","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"2026091106322338900_ref362","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S2213-8587(24)00313-9","article-title":"Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial","volume":"13","author":"Raal","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091106322338900_ref363","volume-title":"Long-Term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-Risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)","author":"NCT04798430"}],"container-title":["Antibody Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/abt\/advance-article-pdf\/doi\/10.1093\/abt\/tbag027\/68424309\/tbag027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/332\/68424309\/tbag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/abt\/article-pdf\/9\/3\/332\/68424309\/tbag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:51Z","timestamp":1789122771000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/abt\/article\/9\/3\/332\/8697373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":363,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,29]]}},"URL":"https:\/\/doi.org\/10.1093\/abt\/tbag027","relation":{},"ISSN":["2516-4236"],"issn-type":[{"value":"2516-4236","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7]]},"published":{"date-parts":[[2026,5,28]]}}}